Towards a unified molecular mechanism for ligand-dependent activation of NR4A-RXR heterodimers
eLife · 2026
DOI: 10.7554/elife.106861 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Xiaoyu Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Vanderbilt University, Nashville, United States. Hauptthemen laut MEDLINE: Retinoid X Receptors, Protein Multimerization, Nuclear Receptor Subfamily 4, Group A, Member 1, Nuclear Receptor Subfamily 4, Group A, Member 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
A subset of nuclear receptors (NRs) function as permissive heterodimers with retinoid X receptor (RXR), defined by transcriptional activation in response to RXR agonist ligands. Permissive NR-RXR activation is generally understood to operate through a classical pharmacological mechanism in which RXR agonist binding enhances coactivator recruitment to the heterodimer. However, we previously demonstrated that transcriptional activation of permissive Nurr1-RXRα (NR4A2-NR2B1) heterodimers by an RXR ligand set, which included pharmacological RXR agonists and selective Nurr1-RXRα agonists that function as antagonists of RXRα homodimers, is explained by a non-classical activation mechanism involving ligand-binding domain (LBD) heterodimer dissociation (Yu et al., 2023). Here, we extend mechanistic ligand profiling of the same RXR ligand set to the evolutionarily related Nur77-RXRγ (NR4A1-NR2B3) heterodimer. Biochemical and NMR protein-protein interaction profiling, together with cellular transcription studies, indicate that activation of Nur77-RXRγ transcription by the RXR ligand set, which lacks selective Nur77-RXRγ agonists, is consistent with contributions from both classical pharmacological activation and LBD heterodimer dissociation. However, reanalysis of our previously published data for Nurr1-RXRα revealed that inclusion of selective Nurr1-RXRα agonists was essential for elucidating the LBD heterodimer dissociation mechanism. Together, our findings highlight the importance of using a more functionally diverse RXR ligand set to define the mechanism of Nur77-RXRγ activation and to further evaluate whether LBD heterodimer dissociation represents a shared activation mechanism among NR4A-RXR heterodimers relevant to neurodegenerative and inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Vanderbilt University, Nashville, United States.
- Department of Integrative Structural and Computational Biology, Scripps Research and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, United States.
- Department of Molecular Medicine, Scripps Research and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, United States.
- Center for Structural Biology, Vanderbilt University, Nashville, United States.
- Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, United States.
- Center for Applied AI in Protein Dynamics, Vanderbilt University, Nashville, United States.
ORCID-Profile: Xiaoyu Yu, Douglas J Kojetin
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Yu, X., He, Y., Kamenecka, T. M., & Kojetin, D. J. (2026). Towards a unified molecular mechanism for ligand-dependent activation of NR4A-RXR heterodimers. eLife. https://doi.org/10.7554/elife.106861
Vancouver
Yu X, He Y, Kamenecka TM, Kojetin DJ. Towards a unified molecular mechanism for ligand-dependent activation of NR4A-RXR heterodimers. eLife. 2026. doi:10.7554/elife.106861
BibTeX
@article{Yu2026,
author = {Yu, Xiaoyu and He, Yuanjun and Kamenecka, Thedore M and Kojetin, Douglas J},
title = {Towards a unified molecular mechanism for ligand-dependent activation of NR4A-RXR heterodimers},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.106861}
}
EUVIMED